Welcome to our dedicated page for Research Alliance IV news (Ticker: RACD), a resource for investors and traders seeking the latest updates and insights on Research Alliance IV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Research Alliance IV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Research Alliance IV's position in the market.
Research Alliance Corporation IV (Nasdaq: RACD), a special purpose acquisition company sponsored by an affiliate of RA Capital Management, priced its $75 million initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market under the ticker “RACD” on July 13, 2026, with closing anticipated on July 14, 2026, subject to customary conditions.
The company is a blank check entity formed to pursue a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination, with an intended focus on healthcare and healthcare-related industries. Leerink Partners is acting as sole bookrunning manager, and multiple institutional investors participated. The SEC declared the registration statement effective on July 10, 2026.